US · Healthcare · Biotechnology
EPS came in at -0.60 against a street estimate of -0.50 — a miss of 20.0%.
Analysts rate Sionna Therapeutics, Inc. Common Stock a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $51.60.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 21.94% |
| TPG GP A, LLC | 14.39% |
| Orbimed Advisors, LLC | 7.82% |
| Viking Global Investors LP | 7.08% |
| Atlas Venture Life Science Advisors, LLC | 6.64% |
| Enavate Sciences GP, LLC | 5.49% |
| JPMorgan Chase & Co | 3.25% |
| Jennison Associates LLC | 3.21% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-18 |
| Quarterly report · Q1 2026 | 2026-05-12 |
| Results announced · Q2 2026 | 2026-05-12 |
| Proxy statement · Q2 2026 | 2026-04-27 |
| Annual report FY2025 | 2026-03-02 |
| Results announced · Q1 2026 | 2026-03-02 |
| Quarterly report · Q3 2025 | 2025-11-05 |
| Results announced · Q4 2025 | 2025-11-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Sionna Therapeutics, Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-08-05.